DMAC · DiaMedica Therapeutics Inc.

DiaMedica Therapeutics reported a Q1 2026 net loss of $10.0 million, up from $7.7 million in the prior year quarter, primarily due to elevated research and development expenses of $8.0 million compared to $5.7 million last year. This increase stemmed from the ongoing global expansion of the ReMEDy2 Phase 2/3 trial for acute ischemic stroke, which has now exceeded 70% of required interim enrollment with analysis slated for 4Q 2026, alongside costs for preeclampsia program expansion and reproductive toxicity testing. General and administrative expenses held steady at $2.5 million. Cash burn intensified with $9.1 million used in operating activities versus $7.1 million prior year, reflecting the net loss growth. Balance sheet remains solid with $51.3 million in cash, cash equivalents, and short-term investments as of March 31, 2026, down from $59.9 million at year-end 2025, providing runway through 2027 to fund clinical studies. Management highlighted advancing DM199 programs, including preeclampsia Phase 2 IST expansion with data due 2Q 2026, early-onset preeclampsia trial site activations in Canada, and fetal growth restriction trial progress. CEO Rick Pauls emphasized upcoming data readouts through 2027 to inform Phase 3 dose selection. R&D expenses are expected to moderately rise, while G&A remains consistent. A conference call is scheduled for May 7, 2026, to elaborate.